Kaminiarczyk-Pyzalka Dominika, Adamczak Karolina, Mikos Hanna, Klimecka Iwona, Moczko Jerzy, Niedziela Marek
Clin Lab. 2014;60(9):1481-90. doi: 10.7754/clin.lab.2013.130734.
The demonstration of the quantitative prevalence of specific cytokines in JIA formed the basis for the introduction of biological anticytokine drugs to treatment. Routine assessment of the concentration of these cytokines in blood serum may enable earlier decision making on the legitimacy of biological treatment (anti-TNF). The aim of the study was to assess the diagnostic value of TNFalpha, IL-6, and IL-1beta in monitoring the course of the disease and effectiveness of treatment with etanercept of children with oligo- and polyarticular JIA.
In a 1-year prospective study, cytokine levels were measured using ELISA in serum samples for 19 JIA patients in whom no clinical improvement was noted in spite of treatment with disease modifying antirheumatic drugs (DMARDs) and glucocorticosteroids (GCS). All the patients started treatment with ETN. The control group included healthy children (n = 18).
Concentrations of TNF-a and IL-6 in blood serum at time 0 were significantly higher than in the control group. IL-6 concentration decreased during treatment with ETN in children in the inactive phase of the disease. Mean concentrations of TNF-a in serum increased several dozen times irrespective of clinical improvement. TNFalpha concentrations were statistically significantly higher in patients in the inactive phase of the disease in comparison with those in the active phase and correlated with the dose of ETN. Only the concentration of IL-6 correlated with the JADAS-27 value at all time points.
We conclude that IL-6 may serve as a biomarker of activity of the disease in children with JIA treated with ETN.
幼年特发性关节炎(JIA)中特定细胞因子定量患病率的证明为生物抗细胞因子药物引入治疗奠定了基础。血清中这些细胞因子浓度的常规评估可能有助于更早地决定生物治疗(抗TNF)的合理性。本研究的目的是评估TNFα、IL-6和IL-1β在监测少关节型和多关节型JIA患儿疾病进程及依那西普治疗效果方面的诊断价值。
在一项为期1年的前瞻性研究中,对19例尽管使用了改善病情抗风湿药物(DMARDs)和糖皮质激素(GCS)治疗但仍无临床改善的JIA患者的血清样本,采用酶联免疫吸附测定法(ELISA)测量细胞因子水平。所有患者均开始使用依那西普(ETN)治疗。对照组包括健康儿童(n = 18)。
0时血清中TNF-α和IL-6的浓度显著高于对照组。疾病非活动期儿童在使用ETN治疗期间IL-6浓度降低。血清中TNF-α的平均浓度增加了几十倍,与临床改善情况无关。疾病非活动期患者的TNFα浓度在统计学上显著高于活动期患者,且与ETN剂量相关。仅IL-6浓度在所有时间点均与JADAS-27值相关。
我们得出结论,IL-6可能是接受ETN治疗的JIA患儿疾病活动的生物标志物。